NCT01221376

Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Renato Melaragno · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the hematological, cytogenetic and molecular response to continuous-use of Imatinib in children with CML Ph+.

Conditions

• Chronic Myeloid Leukemia (CML) With Philadelphia Chromosome-positive (Ph+)

Interventions

Type	Name	Description
DRUG	Imatinib Mesylate	Patient will receive Imatinib Mesylate, continuous-use, 260 mg/m2/day dose, maximum allowed 400 mg, for 24 months.

Timeline

• Start date: 2011-02-01
• Primary completion: 2013-06-01
• Completion: 2013-12-01
• First posted: 2010-10-15
• Last updated: 2013-03-26

Locations

1 site across 1 country: Brazil